Oleptro trazodone regulatory update

Labopharm said Health Canada delayed a decision on an NDS for once-daily trazodone to treat major depressive disorder (MDD) due to an internal backlog at the agency. Labopharm, which originally expected a decision by Aug. 12, now expects a decision by year end. The company said the agency has not informed them of any issues with the application. ...